Trial
NCT04476797
Phase I/II Study of SBRT and GC4711 for Centrally Located or Large NSCLC
Phase ITERMINATEDEFFICACY/FUTILITYConfidence: HIGH
Sponsor
Galera Therapeutics, Inc.
Collaborators
—
Condition
SBRT
Intervention
GC4711 +SBRT
Why stopped
Development GC4711 was halted after the lead study in pancreatic cancer was stopped early due to meeting the requirements of a futility analysis
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-04-30